Jesse G. Dixon

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Amy S. Ruppert, Jesse G. Dixon, Gilles Salles et al. · Blood · 2020 · 378 citations · Full text

Medicine, Hematology, Oncology +12

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo, Jesse G. Dixon, Jennifer Le‐Rademacher et al. · Blood · 2022 · 163 citations · Full text

Medicine, Oncology, Survival Analysis +12

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

Qian Shi, Norbert Schmitz, Fang‐Shu Ou et al. · Journal of Clinical Oncology · 2018 · 108 citations · Full text

Medicine, Oncology, Cancer Control +9

Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database

Dorothea Wagner, Axel Grothey, Thierry André et al. · JNCI Journal of the National Cancer Institute · 2020 · 86 citations · Full text

Medicine, Oncology, Pharmacology +17

Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial

Thomas M. Churilla, Karla V. Ballman, Paul D. Brown et al. · International Journal of Radiation Oncology*Biology*Physics · 2017 · 83 citations

Medicine, Neurosurgery, Oncology +13